Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $0.34
- 200 Day Moving Avg: $0.50
- 52 Week Range: $0.24 - $1.40
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.50
- P/E Growth: 0.00
- Return on Equity: -161.95%
- Return on Assets: -123.71%
- Average Volume: 279,022 shs.
Frequently Asked Questions for Oncolytics Biotech (NASDAQ:ONCY)
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."
How were Oncolytics Biotech's earnings last quarter?
Oncolytics Biotech, Inc. (NASDAQ:ONCY) released its earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. View Oncolytics Biotech's Earnings History.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), XOMA Corporation (XOMA), Protalix Biotherapeutics (PLX), Concordia International Corp (CXR), ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Wayne F. Pisano, Chairman of the Board
- Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
- Kirk J. Look, Chief Financial Officer
- George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
- Mary Ann Dillahunty J.D., Vice President - Intellectual Property
- Andres A. Gutierrez M.D., PhD., Chief Medical Officer
- Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer
- Angela Frances Holtham, Director
- Edwin Levy Ph.D., Director
- J. Mark Lievonen, Director
How do I buy Oncolytics Biotech stock?
Shares of Oncolytics Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncolytics Biotech's stock price today?
MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Oncolytics Biotech stock can currently be purchased for approximately $0.33.
Consensus Ratings for Oncolytics Biotech (NASDAQ:ONCY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Oncolytics Biotech (NASDAQ:ONCY)
(Data available from 9/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/3/2016||Royal Bank Of Canada||Reiterated Rating||Outperform||N/A|
Earnings History for Oncolytics Biotech (NASDAQ:ONCY)Earnings History by Quarter for Oncolytics Biotech (NASDAQ ONCY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Oncolytics Biotech (NASDAQ:ONCY)
Current Year EPS Consensus Estimate: $-0.18 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS
Dividend History for Oncolytics Biotech (NASDAQ:ONCY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Oncolytics Biotech (NASDAQ:ONCY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Oncolytics Biotech (NASDAQ:ONCY)
Latest Headlines for Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech (ONCY) Chart for Tuesday, September, 26, 2017